Lipid Disorder Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Lipid Disorder Treatment Market Analysis
The major factors attributing to the growth of the lipid disorder treatment market are the growing prevalence of lifestyle diseases like obesity and increasing smoking and alcohol consumption. Lifestyle diseases are conditions associated with the way people live. They include atherosclerosis, heart disease, stroke, obesity, and type 2 diabetes. As per the World Health Organization (WHO), in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese, However, in 2018, 40 million children under the age of 5 were overweight or obese.
Furthermore, the increasing growth of familial combined hyperlipidemia incidence rate also plays a major role in the growth of the market. However, the side effects of the medication involved in the treatment are the restraint to the growth of the market.
Lipid Disorder Treatment Market Trends
This section covers the major market trends shaping the Lipid Disorder Treatment Market according to our research experts:
Familial Combined Hyperlipidemia Incidence Rate is Expected to Show a High Growth
Familial combined hyperlipidemia is the most common congenital disorder that increases blood fats. It causes high cholesterol and high blood triglycerides which can cause early heart attacks. The rate of incidence of this disease is high in adults, and the treatment market for the disease is profitable for the key players involved in the manufacturing of the drugs. As this condition is common, the drugs for this disease have maximum sales and generates maximum revenue.
Statins are the class of drugs that are used to treat familial combined hyperlipidemia, the same is used to treat related conditions like obesity. Therefore as the incidence of obesity increases the market growth rate of this segment also increases.
As per the National Organization for Rare Disorders(NORD), 1 in 220 people have familial combined hyperlipidemia and these statistics prove that the increasing patient pool is directly proportional to the market growth.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall lipid disorder treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of obesity and other lifestyle disorders in the region, established healthcare infrastructure, are some of the key factors accountable for its large share in the market.
Furthermore, higher incidence of familial combined hyperlipidemia, beneficial government initiatives and increase awareness of the treatment are some of the drivers expected to increase the market growth. In the North America region, the United States holds the largest market share. According to Center for Chronic Disease Prevention (CDC), 7% of U.S. children and adolescents ages 6 to 19 have high total cholesterol, therefore a growing number of these diseases in the country is anticipated to stimulate the demand in this region.
Lipid Disorder Treatment Industry Overview
The lipid disorder treatment market is moderately competitive and consists of major players. Some of the companies which are currently domianting the market Pfizer, Inc, Novartis AG, Astrazeneca Plc, Merck & Co., Inc., Sun Pharma, Emcure Pharmaceuticals, Teva Pharmaceuticals, Mylan Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Glenmark Pharmaceuticals Ltd., Wockhardt Limited.
Lipid Disorder Treatment Market Leaders
Pfizer, Inc
Novartis AG
Astrazeneca Plc
Merck & Co., Inc
Sun Pharma
*Disclaimer: Major Players sorted in no particular order
Lipid Disorder Treatment Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increase in Prevalence of Several Lifestyle Diseases
-
4.2.2 Rise in the Smoking and Alcohol Consumption
-
-
4.3 Market Restraints
-
4.3.1 Side effects of the treatment
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Indication
-
5.1.1 Hypercholesterolemia
-
5.1.2 Dysbetalipoproteinemia
-
5.1.3 Familial Combined Hyperlipidemia
-
5.1.4 Others
-
-
5.2 By Distribution Channel
-
5.2.1 Hospital Pharmacies
-
5.2.2 Retail Pharmacies
-
5.2.3 Online Pharmacies
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle-East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle-East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Pfizer, Inc
-
6.1.2 Novartis AG
-
6.1.3 Astrazeneca Plc
-
6.1.4 Merck & Co. Inc.
-
6.1.5 Emcure Pharmaceuticals Ltd.
-
6.1.6 Ranbaxy Laboratories Ltd.
-
6.1.7 Teva Pharmaceuticals
-
6.1.8 Mylan Pharmaceuticals, Inc.
-
6.1.9 Kowa Pharmaceuticals America, Inc.
-
6.1.10 Glenmark Pharmaceuticals Ltd.
-
6.1.11 Sun Pharmaceuticals Industries Ltd.
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Lipid Disorder Treatment Industry Segmentation
As per the scope of the report, lipid disorders comprise a broad spectrum of conditions where the blood lipid levels are affected. Generally, it is associated with an increase in the blood lipid levels.
| By Indication | |
| Hypercholesterolemia | |
| Dysbetalipoproteinemia | |
| Familial Combined Hyperlipidemia | |
| Others |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Lipid Disorder Treatment Market Research FAQs
What is the current Lipid Disorder Treatment Market size?
The Lipid Disorder Treatment Market is projected to register a CAGR of 7.80% during the forecast period (2024-2029)
Who are the key players in Lipid Disorder Treatment Market?
Pfizer, Inc, Novartis AG, Astrazeneca Plc, Merck & Co., Inc and Sun Pharma are the major companies operating in the Lipid Disorder Treatment Market.
Which is the fastest growing region in Lipid Disorder Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Lipid Disorder Treatment Market?
In 2024, the North America accounts for the largest market share in Lipid Disorder Treatment Market.
What years does this Lipid Disorder Treatment Market cover?
The report covers the Lipid Disorder Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Lipid Disorder Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Lipid Disorder Treatment Industry Report
Statistics for the 2024 Lipid Disorder Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Lipid Disorder Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
